Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

trisalus life sciences inc - TLSI

TLSI

Close Chg Chg %
7.05 0.01 0.14%

Pre-Market

7.06

+0.01 (0.14%)

Volume: 32.72K

Last Updated:

Dec 24, 2025, 1:00 PM EDT

Trade Now

Company Overview: trisalus life sciences inc - TLSI

TLSI Key Data

Open

$7.04

 Day Range

6.99 - 7.28

52 Week Range

3.42 - 7.95

 Market Cap

$352.25M

Shares Outstanding

49.96M

 Public Float

30.35M

Beta

0.43

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.02

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

241.32K

  

TLSI Performance

1 Week
 
 -4.99%
 
1 Month
 
 2.62%
 
3 Months
 
 50.00%
 
1 Year
 
 45.66%
 
5 Years
 
 N/A
 

TLSI Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About trisalus life sciences inc - TLSI

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020, and is headquartered in Westminster, CO.

TLSI At a Glance

TriSalus Life Sciences, Inc.
6272 West 91st Avenue
Westminster, Colorado 80031
Phone 1-888-321-5212 Revenue 29.43M
Industry Medical Specialties Net Income -30,045,000.00
Sector Health Technology 2024 Sales Growth 58.992%
Fiscal Year-end 12 / 2025 Employees 110
View SEC Filings

TLSI Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 4.312
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -4.039
Enterprise Value to Sales 4.825
Total Debt to Enterprise Value 0.166

TLSI Efficiency

Revenue/Employee 267,554.545
Income Per Employee -273,136.364
Receivables Turnover 5.786
Total Asset Turnover 1.184

TLSI Liquidity

Current Ratio 2.021
Quick Ratio 1.625
Cash Ratio 0.833

TLSI Profitability

Gross Margin 83.531
Operating Margin -122.881
Pretax Margin -102.066
Net Margin -102.086
Return on Assets -120.915
Return on Equity N/A
Return on Total Capital 1,326.49
Return on Invested Capital N/A

TLSI Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital -1,043.223
Total Debt to Total Assets 98.573
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital -1,033.687
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Trisalus Life Sciences Inc - TLSI

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - 18.51M 29.43M
-
Sales Growth
- - - +58.99%
-
Cost of Goods Sold (COGS) incl D&A
- - 3.29M 4.85M
-
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- - 715.00K 1.01M
-
Depreciation
- - - 697.00K
-
Amortization of Intangibles
- - - 18.00K
-
COGS Growth
- - - +47.37%
-
Gross Income
- - 15.22M 24.58M
-
Gross Income Growth
- - - +61.50%
-
Gross Profit Margin
- - +82.23% +83.53%
-
2021 2022 2023 2024 5-year trend
SG&A Expense
3.04M 2.75M 64.05M 60.75M
Research & Development
- - 28.51M 17.69M
-
Other SG&A
3.04M 2.75M 35.53M 43.06M
SGA Growth
+2,702.68% -9.69% +2,232.20% -5.15%
Other Operating Expense
- - - -
-
Unusual Expense
(7.74M) (5.84M) 10.24M (9.12M)
EBIT after Unusual Expense
4.70M 3.09M (59.07M) (27.04M)
Non Operating Income/Expense
64.00K 3.02M 54.00K 92.00K
Non-Operating Interest Income
64.00K 3.02M 431.00K 404.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 16.00K 3.09M
-
Interest Expense Growth
- - - +19,212.50%
-
Gross Interest Expense
- - 16.00K 3.09M
-
Interest Capitalized
- - - -
-
Pretax Income
4.77M 6.11M (59.03M) (30.04M)
Pretax Income Growth
+770.14% +28.16% -1,066.12% +49.11%
Pretax Margin
- - -318.89% -102.07%
-
Income Tax
- 570.85K 9.00K 6.00K
Income Tax - Current - Domestic
- 1.08M 9.00K 6.00K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - (513.46K)
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
4.77M 5.54M (59.04M) (30.05M)
Minority Interest Expense
- - - -
-
Net Income
4.77M 5.54M (59.04M) (30.05M)
Net Income Growth
+770.14% +16.19% -1,165.85% +49.11%
Net Margin Growth
- - -318.93% -102.09%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
4.77M 5.54M (59.04M) (30.05M)
Preferred Dividends
- - 4.24M 3.19M
-
Net Income Available to Common
4.77M 5.54M (63.28M) (33.23M)
EPS (Basic)
0.1526 0.1871 -6.7346 -1.3119
EPS (Basic) Growth
+769.30% +22.61% -3,699.47% +80.52%
Basic Shares Outstanding
31.25M 29.61M 9.40M 25.33M
EPS (Diluted)
0.1526 0.1871 -6.7346 -1.3119
EPS (Diluted) Growth
+769.30% +22.61% -3,699.47% +80.52%
Diluted Shares Outstanding
31.25M 29.61M 9.40M 25.33M
EBITDA
(3.04M) (2.75M) (48.11M) (35.16M)
EBITDA Growth
-2,702.76% +9.69% -1,651.85% +26.92%
EBITDA Margin
- - -259.89% -119.46%
-

Snapshot

Average Recommendation BUY Average Target Price 11.357
Number of Ratings 7 Current Quarters Estimate -0.123
FY Report Date 12 / 2025 Current Year's Estimate -1.754
Last Quarter’s Earnings -0.96 Median PE on CY Estimate N/A
Year Ago Earnings -1.31 Next Fiscal Year Estimate -0.189
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 6 5 7
Mean Estimate -0.12 -0.07 -1.75 -0.19
High Estimates -0.09 -0.02 -1.70 -0.04
Low Estimate -0.17 -0.10 -1.79 -0.50
Coefficient of Variance -19.78 -42.38 -2.16 -86.08

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 7
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Trisalus Life Sciences Inc - TLSI

Date Name Shares Transaction Value
Nov 26, 2025 Mary T. Szela CEO and President; Director 317,802 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Mary T. Szela CEO and President; Director 442,802 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Mary T. Szela CEO and President; Director 742,802 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Mary T. Szela CEO and President; Director 1,578,182 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Jodi Devlin Chief of Clinical Operations 100,571 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Jodi Devlin Chief of Clinical Operations 463,750 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Richard B. Marshak Chief Commercial Officer 113,854 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Richard B. Marshak Chief Commercial Officer 408,937 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Bryan F. Cox Chief of Research 166,599 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Bryan F. Cox Chief of Research 261,954 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 David Patience Chief Financial Officer 265,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 David Patience Chief Financial Officer 668,899 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Jennifer L. Stevens Chief Regulatory Officer 127,640 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Jennifer L. Stevens Chief Regulatory Officer 323,782 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Sean E. Murphy Chief Manuf, Strategy&Bus Dev.; Director 79,105 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 James E. Young Chief Financial Officer 36,488 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Trisalus Life Sciences Inc in the News